Advertisement
UK markets closed

  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     

  • FTSE 250

    20,286.03
    -45.77 (-0.23%)
     

  • AIM

    764.38
    -0.09 (-0.01%)
     

  • GBP/EUR

    1.1796
    -0.0009 (-0.07%)
     

  • GBP/USD

    1.2648
    +0.0006 (+0.05%)
     

  • Bitcoin GBP

    48,095.59
    -464.83 (-0.96%)
     

  • CMC Crypto 200

    1,267.90
    -15.93 (-1.24%)
     

  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     

  • DOW

    39,118.86
    -45.20 (-0.12%)
     

  • CRUDE OIL

    81.46
    -0.28 (-0.34%)
     

  • GOLD FUTURES

    2,336.90
    +0.30 (+0.01%)
     

  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     

  • HANG SENG

    17,718.61
    +2.14 (+0.01%)
     

  • DAX

    18,235.45
    +24.90 (+0.14%)
     

  • CAC 40

    7,479.40
    -51.32 (-0.68%)
     
Property :

8 UK holiday home businesses you could buy now

A holiday let could be a very sound investment, providing a decent income, capital growth and — somewhere to escape

Endometriosis Drug Pipeline Landscape 2024: Insights About 15+ Companies and 20+ Pipeline Drugs

Research and Markets
·5-min read
Company Logo
Company Logo

Dublin, June 17, 2024 (GLOBE NEWSWIRE) -- The "Endometriosis - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Endometriosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endometriosis pipeline landscape is provided which includes the disease overview and Endometriosis treatment guidelines. The assessment part of the report embraces, in depth Endometriosis commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endometriosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Endometriosis R&D. The therapies under development are focused on novel approaches to treat/improve Endometriosis.

Endometriosis Emerging Drugs Chapters

This segment of the Endometriosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Endometriosis Emerging Drugs

Linzagolix: ObsEva

Linzagolix, is a novel, orally administered GnRH receptor antagonist with a potentially best-in-class profile in late-stage clinical development for the treatment of endometriosis-associated pain. Linzagolix acts by binding to and blocking the GnRH receptor in the pituitary gland, ultimately dose-dependently reducing estrogen production by the ovaries.

ADVERTISEMENT

Through previously reported results from linzagolix it has been established that maintaining estradiol within a specific target range provides the optimal balance between reducing symptoms while mitigating bone density loss associated with excessive estradiol suppression. In 2015, ObsEva in-licensed Linzagolix from Kissei Pharmaceutical Co., which had completed several Phase II clinical trials in Japan. Currently, the drug is in Phase III stage of its development for the treatment of endometriosis.

HMI-115: Hope Medicine (Nanjing) Co., Ltd

HMI-115 is a first-in-class monoclonal antibody drug that Hope Medicine owns the global rights. In April 2019, Hope Medicine and Bayer AG signed an exclusive global license agreement for the development and commercialization of HMI-115, a monoclonal antibody targeting the prolactin receptor (PRLR), for multiple indications globally.

Potential indications for the antibody include Endometriosis (EM), Androgenic Alopecia (AGA), and other chronic diseases. In 2021, Hope Medicine received approval from the FDA and EMA to conduct MRCT Phase II clinical trials for the treatment of endometriosis Hope Medicine has now completed patient enrollment and dosing at all clinical trial centers in the US and Europe. In November 2022, HMI-115 received clinical trial approval from the NMPA. Currently, the drug is in Phase II stage of its development for the treatment of endometriosis.

VAL-301: ValiRx

VAL-301 is a small molecule, peptide, and new chemical entity it is developed in-house by ValiRx, under evaluation by an undisclosed Japanese Pharmaceutical Company. VAL301 peptide re-purposed towards non-cancerous cell proliferation. The mechanism of action of drug candidate is inhibition of androgen activation of SRC kinase. Currently, the drug is in preclinical stage of its development for the treatment of endometriosis.

Endometriosis: Therapeutic Assessment

This segment of the report provides insights about the different Endometriosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Endometriosis

  • There are approx. 15+ key companies which are developing the therapies for Endometriosis. The companies which have their Endometriosis drug candidates in the most advanced stage, i.e. Phase III include, ObsEva.

Key Questions

  • How many companies are developing Endometriosis drugs?

  • How many Endometriosis drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Endometriosis?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Endometriosis therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Endometriosis and their status?

  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • ObsEva

  • Jiangsu HengRui Medicine Co., Ltd.

  • Hope Medicine (Nanjing) Co., Ltd

  • ValiRx

  • BCI Pharma

  • Mithra Pharmaceuticals

  • Debiopharm

  • Forendo Pharma Ltd

  • TiumBio

  • EpicentRx

  • Flightpath Biosciences

  • Antev

Key Products

  • Linzagolix

  • SHR7280

  • HMI-115

  • VAL-301

Research programme: macrophage colony stimulating factor receptor 1 kinase inhibitors

  • Drospirenone/estetrol

  • Triptorelin

  • FOR-6219

  • Merigolix

  • Nibrozetone

  • FP-300

  • Teverelix trifluoroacetate

Phases

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

  • Oral

  • Intravenous

  • Subcutaneous

  • Parenteral

  • Topical

  • Molecule Type

Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

  • Product Type

Endometriosis Report Insights

  • Endometriosis Pipeline Analysis

  • Therapeutic Assessment

  • Unmet Needs

  • Impact of Drugs

Endometriosis Report Assessment

  • Pipeline Product Profiles

  • Therapeutic Assessment

  • Pipeline Assessment

  • Inactive drugs assessment

  • Unmet Needs

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/pymf0r

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900